Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
Rolfo C, Sortino G, Smits E, Passiglia F, Bronte G, Castiglia M, Russo A, Santos ES, Janssens A, Pauwels P, Raez L. Rolfo C, et al. Expert Rev Anticancer Ther. 2014 Oct;14(10):1173-87. doi: 10.1586/14737140.2014.952287. Epub 2014 Aug 22. Expert Rev Anticancer Ther. 2014. PMID: 25148289 Review.
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P. Rolfo C, et al. Among authors: raez le. Transl Lung Cancer Res. 2014 Aug;3(4):250-61. doi: 10.3978/j.issn.2218-6751.2014.03.01. Transl Lung Cancer Res. 2014. PMID: 25806308 Free PMC article. Review.
Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C, Grassi M, Raez L, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C. Caglevic C, et al. Ther Adv Respir Dis. 2015 Aug;9(4):164-72. doi: 10.1177/1753465815579608. Epub 2015 Apr 7. Ther Adv Respir Dis. 2015. PMID: 25855060 Free article. Review.
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L. Rolfo C, et al. Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12. Expert Opin Investig Drugs. 2015. PMID: 26457764 Review.
186 results